CEO Jan Kengelbach about Trends in CDMO Market (Interview in GBR Life Sciences Report 2023)
In the latest edition of Global Business Reports' renowned US Life Sciences 2023 Report, Aenova outlines not only trends in the CDMO market but also highlights in capacities and capabilities at Aenova.
In the interview, Aenova CEO Jan Kengelbach also explains latest achievements:
"(...) About four years ago, we designed a new growth strategy. First, each site had to become a center of excellence for a certain technology, and second, in each site, we made the investment decisions to either expand existing capacities or extend the technology offering. In total, there are 15 new growth platforms at Aenova now, of which eight are commercially online yet. As an example of capacity expansion, we extended our high-volume Tittmoning site, Germany, to 10bn tablet capacity. We created a brand new sterile area fill and finish area (including biologics) for prefilled syringes and RTU vials at our Latina Site, Italy. The breadth of new technologies that we have put online is including the new high-potent API facility at our Regensburg site, Germany, the hot melt extrusion and templated inverted particles at our Sisseln site, Switzerland, or the new dry powder inhaler/microdosed capsule filling at our Münster site, Germany (...)."